Hengrui Medicine (600276.SH): SHR-4506 injection liquid obtained approval for clinical drug trials.

Smart Finance and Economics APP News, Hengrui Medicine (600276.SH) issued an announcement, recently, the company's subsidiary Suzhou Shengdiya Biopharmaceutical Co., Ltd. received the National Medical Products Administration's ("NMPA") approval to issue the "Drug Clinical Trial Approval Notice" for SHR-4506 injection, and will soon start clinical trials.